Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant ‐level pooled analysis of DAPA‐HF and DELIVER
ConclusionHistory of MI confers increased risks of adverse cardiovascular outcomes in patients with HF across the LVEF spectrum, even among those with preserved ejection fraction. Dapagliflozin consistently and safely reduces the risk of cardiovascular death or worsening HF, regardless of previous MI. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 15, 2024 Category: Cardiology Authors: Alexander Peikert, Muthiah Vaduganathan, Brian L. Claggett, Ian J. Kulac, Alberto Fo à, Akshay S. Desai, Pardeep S. Jhund, Jaclyn Carberry, Carolyn S.P. Lam, Mikhail N. Kosiborod, Silvio E. Inzucchi, Felipe A. Martinez, Rudolf A. de Boer, Ad Tags: Research Article Source Type: research

Efficacy and safety of the Aria pulmonary endovascular device in pulmonary hypertension
ConclusionsTemporary implantation of the Aria endovascular device was feasible and safe. Device activation resulted in acute improvement of CPA and RV-PV coupling. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 14, 2024 Category: Cardiology Authors: Christian Gerges, Karl Vollmers, Nika Skoro ‐Sajer, Varius Dannenberg, Valerie Hartig, Marc R. Pritzker, John Scandurra, E. Kenneth Weir, Irene M. Lang Tags: Research Article Source Type: research

Sodium –glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction
ConclusionsTreatment with SGLT2i influenced skeletal muscle pathology in patients with HFrEF and was associated with anti-atrophic, anti-inflammatory, and pro-metabolic effects. These changes may be regulatedvia IL-6 –kynurenine signalling. Together, clinical improvements following SGLT2i treatment in patients with HFrEF may be partly explained by their positive effects on skeletal muscle pathology. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 12, 2024 Category: Cardiology Authors: Nathanael Wood, Sam Straw, Chew W. Cheng, Yu Hirata, Marcelo G. Pereira, Harrison Gallagher, Stuart Egginton, Wataru Ogawa, Stephen B. Wheatcroft, Klaus K. Witte, Lee D. Roberts, T. Scott Bowen Tags: Research Article Source Type: research

The salt paradox in heart failure
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 12, 2024 Category: Cardiology Authors: Zachary L. Cox, Jeffrey M. Testani Tags: Invited Editorial Source Type: research

Implications of tricuspid regurgitation and right ventricular volume overload in patients with heart failure with preserved ejection fraction
ConclusionDiastolic LV properties in patients with HFpEF and severe TR are importantly determined by ventricular interaction in the setting of RV volume overload. T-TEER reduces RV volume overload and improves biventricular interaction and physiology. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 11, 2024 Category: Cardiology Authors: Karl ‐Patrik Kresoja, Sebastian Rosch, Anne Rebecca Schöber, Karl Fengler, Florian Schlotter, Sara Bombace, Paula Sagmeister, Maximilian von Roeder, Tobias Kister, Matthias Gutberlet, Holger Thiele, Karl‐Philipp Rommel, Philipp Lurz Tags: Research Article Source Type: research

Changes in right ventricular function and clinical outcomes following tricuspid transcatheter edge ‐to‐edge repair
ConclusionPost-procedural increase in RVFAC after T-TEER is associated with improved outcomes in patients with RV dysfunction. The factors related to the increase in RVFAC may support patient selection for T-TEER in patients with RV dysfunction. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 8, 2024 Category: Cardiology Authors: Tetsu Tanaka, Atsushi Sugiura, Refik Kavsur, Can Öztürk, Nihal Wilde, Sebastian Zimmer, Georg Nickenig, Marcel Weber, Johanna Vogelhuber Tags: Research Article Source Type: research

Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial
ConclusionsLoop diuretic TDD at randomization was independently associated with worse outcomes in this high-risk population. The efficacy of vericiguat was consistent across the range of diuretic doses. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 7, 2024 Category: Cardiology Authors: Justin Ezekowitz, Wendimagegn Alemayehu, Frank Edelmann, Piotr Ponikowski, Carolyn S.P. Lam, Christopher M. O'Connor, Javed Butler, Stefano Corda, Ciaran J. McMullan, Cynthia M. Westerhout, Adriaan A. Voors, Robert J. Mentz, Paul W. Armstrong, Tags: Research Article Source Type: research

Weight telemonitoring of heart failure versus standard of care in a real ‐world setting: Results on mortality and hospitalizations in a 6‐month nationwide matched cohort study
ConclusionThe results of this nationwide cohort study highlight a valuable role for telemonitoring solutions such as CCC in the management of high-risk HF patients. However, for telemonitoring solutions based on weight and symptoms, consideration should be given to implement additional methods of assessment to recognize imminent worsening of HF, such as impedance changes, as a way to reduce mortality risk and the need for HF hospitalizations. Further studies are warranted to refine selection of patients who could benefit from a telemonitoring system and to confirm long-term benefits in high-risk and stable HF patients. (So...
Source: European Journal of Heart Failure - March 7, 2024 Category: Cardiology Authors: Fran çois Roubille, Grégoire Mercier, Guila Lancman, Hélène Pasche, Sarah Alami, Cécile Delval, Antoine Bessou, Jade Vadel, Amayelle Rey, Stéphanie Duret, Emilie Abraham, Gilles Chatellier, Isabelle Durand Zaleski Tags: Research Article Source Type: research

Blood pressure and intensive treatment up ‐titration after acute heart failure hospitalization: Insights from the STRONG‐HF trial
ConclusionsIn STRONG-HF, the benefits of HIC versus UC were independent of baseline SBP. Rapid GDMT up-titration was performed also in patients with an early SBP drop, resulting in similar 180-day outcome as compared to patients with stable or increased SBP. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 6, 2024 Category: Cardiology Authors: Matteo Pagnesi, Oscar Alberto Gomez Vilamaj ó, Alejandro Meiriño, Carlos Alberto Dumont, Alexandre Mebazaa, Beth Davison, Marianna Adamo, Mattia Arrigo, Marianela Barros, Jan Biegus, Jelena Celutkiene, Kamilė Čerlinskaitė‐Bajorė, Ovidi Tags: Research Article Source Type: research

Iron replacement therapy in heart failure: Contextualizing the results of the HEART ‐FID trial
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 5, 2024 Category: Cardiology Authors: Javed Butler, Robert J. Mentz, Adrian F. Hernandez Tags: Viewpoint Source Type: research

Effect of long ‐term tafamidis treatment on health‐related quality of life in patients with transthyretin amyloid cardiomyopathy
ConclusionTafamidis reduced HRQoL decline in patients with ATTR-CM. Patients continuously treated with tafamidis for 60 months demonstrated stabilized HRQoL. In patients who initially received placebo in ATTR-ACT, tafamidis reduced the decline in HRQoL during the LTE study. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 5, 2024 Category: Cardiology Authors: Martha Grogan, Margot K. Davis, Maria G. Crespo ‐Leiro, Marla B. Sultan, Balarama Gundapaneni, Franca Stedile Angeli, Mazen Hanna Tags: Short Report Source Type: research

‘Micro’‐managing heart failure: Restoring that which was lost in translation
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 5, 2024 Category: Cardiology Authors: A. Mark Richards, Peipei Wang, Lee Lee Wong Tags: Invited Editorial Source Type: research

Prevalence of wild ‐type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: Results of the Amylo‐VIP‐HF study
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 5, 2024 Category: Cardiology Authors: Alwin Tubben, Hendrea S.A. Tingen, Niek H.J. Prakken, Vanessa P.M. van Empel, Thomas M. Gorter, Laura M.G. Meems, Olivier C. Manintveld, Michiel Rienstra, Robert G. Tieleman, Andor W.J.M. Glaudemans, Dirk J. van Veldhuisen, Riemer H.J.A. Slart, Tags: Research Letter Source Type: research

Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR ‐Preserved analysis
ConclusionIn EMPEROR-Preserved, LRTI was frequent and associated with a poor prognosis. Empagliflozin was associated with a reduced risk of LRTI compared to placebo. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 5, 2024 Category: Cardiology Authors: Jo ão Pedro Ferreira, Faiez Zannad, Milton Packer, Gerasimos Filippatos, Stuart J. Pocock, Francisco Vasques‐Nóvoa, Michael Böhm, Javed Butler, Stefan Anker Tags: Research Article Source Type: research

Association of diabetes ‐specific heart failure risk score with presence of subclinical cardiomyopathy among individuals with diabetes: A prospective study
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 5, 2024 Category: Cardiology Authors: Zainali S. Chunawala, Neil Keshvani, Matthew W. Segar, Kershaw V. Patel, Muhammad Shariq Usman, Vinayak Subramanian, Viraj Raygor, Alvin Chandra, Muhammad Shahzeb Khan, Ambarish Pandey Tags: Research Letter Source Type: research